This application is a resubmission of the application submitted in response to RFA-CA-09-022. We appreciate the comments from the reviewers following that submission. The areas of concern have been reviewed and we have reworked the document to address those areas. The VMCCOP has been in existence since 1983 and is one of 27 CCOP grants continuously funded. Our CCOP is comprised of 6 hospital based practices spanning over Washington and Alaska. The VMCCOP core component is comprised of Virginia Mason Medical Center (VMMC) and 5 additional satellite locations in the greater Seattle area. Our component sites include Fairbanks Cancer Treatment Center (Fairbanks Memorial Hospital), Fairbanks AK;Providence Cancer Center (Providence Alaska Medical Center), Anchorage AK;Evergreen Medical Center, Kirkland WA;Valley Medical Center, Renton WA;and Pacific Medical Center, Seattle WA. It is the intent of the VMCCOP to continue to expand clinical research opportunities for our cancer patients.
Specific aims of the VMCCOP are outlined below: 1. Maintain and continue our growth in enrollment to treatment and cancer control trials. 2. Increase affiliation participation surrounding enrollment and national participation. 3. Continue to improve our quality and data integrity surrounding our clinical trials. 4. Improve upon our research efficiency by creating standards surrounding study start-up, coordinator hand-offs and subject visits.

Public Health Relevance

It is estimated that there will be 1,529,560 new cancer cases diagnosed in the United States in 2010, and 569,490 cancer deaths. In providing access to clinical research trials in the treatment and prevention of cancer to the patient population throughout Washington and Alaska, the VMCCOP hopes to contribute to reductions in cancer incidence and mortality.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA035192-29S1
Application #
8850954
Study Section
Special Emphasis Panel (ZCA1-SRLB-B (J1))
Program Officer
St Germain, Diane
Project Start
1983-09-01
Project End
2014-07-31
Budget Start
2014-06-01
Budget End
2014-07-31
Support Year
29
Fiscal Year
2014
Total Cost
$86,403
Indirect Cost
$35,557
Name
Benaroya Research Institute at Virginia Mason
Department
Type
DUNS #
076647908
City
Seattle
State
WA
Country
United States
Zip Code
98101
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Mata, Douglas A; Groshen, Susan; Von Rundstedt, Friedrich-Carl et al. (2015) Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol 111:923-8
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
von Rundstedt, Friedrich-Carl; Mata, Douglas A; Groshen, Susan et al. (2015) Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int 116:44-9
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7

Showing the most recent 10 out of 130 publications